The DCCT is a multicenter cooperative trial in which 21 centers are participating to determine whether normalization of the blood glucose level of Type I (insulin-dependent) patients can prevent the complications of retinopathy, nephropathy and cardiovascular disease. Two of the four phases of the study have been completed: Phase I, the protocol was designed; Phase II, patients were recruited, randomized and observed for feasibility and safety of normoglycemia. The NYH-CUMC recruited 15 patients in Phase II although only 12 were required. Since the clinics were notified to begin recruitment for Phase III, the New York Hospital-Cornell University Medical Center has randomized five patients and, thus, are ahead of the recommended December deadline. No difficulty is anticipated in meeting future recruitment goals. The greater New York- Metropolitan area has a population of approximately 13,000,000, which includes many individuals with Type I diabetes. The New York Hospital-Cornell University Medical Center is a large teaching hospital complex which enjoys a superb reputation in the surrounding community. The Clinic is geographically ideally situated in mid-town Manhattan and is readily accessible by public transportation; therefore, it is in an excellent environment for accomplishing the goals of the study.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK030627-09
Application #
3550586
Study Section
Special Emphasis Panel (ADDK (17))
Project Start
1982-03-01
Project End
1994-06-30
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
Schools of Medicine
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065